Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:15 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2089–2112 of 2,274 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Ovary Disease Clear all

Conditions: Primary Peritoneal Carcinoma, Recurrent Ovarian Carcinoma
Interventions: Paclitaxel Poliglumex; Drug
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 18 Years and older · Female only
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Ovarian Neoplasms
Interventions: TLK286 HCl for injection, topotecan hydrochloride for injection, doxorubicin HCl liposome injection; Drug
Lead sponsor: Telik; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 234
States / cities: Little Rock, Arkansas • Baldwin Park, California • Burbank, California + 146 more

Conditions: Gynecologic Cancer, Gynecologic Neoplasms, Peritoneal Carcinomatosis, Peritoneal Neoplasms, Ovarian Cancer, Ovarian Neoplasms, Colorectal Cancer, Colorectal Neoplasms, Appendiceal Cancer, Appendiceal Neoplasms, Cholangiocarcinoma, Breast Cancer
Interventions: Paclitaxel, Nilotinib, ECG, CT Scan CAP, Laparoscopy, Peritoneal biopsies + ascites washings; Drug · Diagnostic Test · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Colorectal Cancer, Gastric Cancers, Ovarian Cancers, Pancreatic Ductal Adenocarcinoma
Interventions: GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT); Drug
Lead sponsor: GE Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Grand Rapids, Michigan

Conditions: Polycystic Ovary Syndrome
Interventions: Elix Daily Harmony, Elix Cycle Balance; Other
Lead sponsor: Zenchi, Inc.; Industry
Eligibility: 18 Years to 36 Years · Female only
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Polycystic Ovary Syndrome
Interventions: Inositol supplement, Placebo supplement; Dietary Supplement
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 36 Years
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Ovarian Neoplasm
Interventions: Dostarlimab, Bevacizumab, Niraparib; Drug
Lead sponsor: Tesaro, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 10
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 6 more

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Ovarian Cancer Stage III, Ovarian Cancer Stage IV, Fallopian Tube Cancer Stage IV, Fallopian Tube Cancer Stage III
Interventions: Microdevice; Combination Product
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Polycystic Ovary Syndrome, Insulin Resistance
Interventions: Cinnamon Supplementation, Placebo (wheat flour); Dietary Supplement
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 20 Years to 40 Years · Female only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Solid Tumor
Interventions: RMC-4630, Cobimetinib, Drug: Osimertinib; Drug
Lead sponsor: Revolution Medicines, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 21
States / cities: Scottsdale, Arizona • Duarte, California • Orange, California + 18 more

Conditions: Recurrent Ovarian Cancer
Interventions: DOXIL, Withaferin A, Ashwagandha, Combination of ASWD and DOXIL; Drug
Lead sponsor: Sham Sunder Kakar; Other
Eligibility: 18 Years and older · Female only
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Ovarian Cancer, Melanoma, Triple Negative Breast Cancer, Colorectal Cancer
Interventions: NM1F Injection, Pembrolizumab injection; Drug
Lead sponsor: Hefei TG ImmunoPharma Co., Ltd.; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Dallas, Texas • Fairfax, Virginia

Conditions: Ovarian Cancer
Interventions: Fertility-Sparing Survey; Behavioral
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Pancreatic Ductal, Tumor Virus Infections
Interventions: CC-486, Carboplatin, ABI-007; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 7
States / cities: Scottsdale, Arizona • San Francisco, California • Indianapolis, Indiana + 4 more

Conditions: Ovarian Cancer
Interventions: 90Y-hu3S193, 111In-hu3S193; Biological
Lead sponsor: Ludwig Institute for Cancer Research; Other
Eligibility: 18 Years and older · Female only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: New York, New York

Conditions: Polycystic Ovary Syndrome, Anovulation, Oligoovulation, Infertility, Hyperandrogenism
Interventions: Metformin, Clomiphene citrate, Placebo; Drug
Lead sponsor: 59th Medical Wing; Federal
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1997 – 2003
U.S. locations: 1
States / cities: Lackland Air Force Base, Texas

Conditions: Leukemia, Long-term Effects Secondary to Cancer Therapy in Adults, Long-term Effects Secondary to Cancer Therapy in Children, Lymphoma, Sexual Dysfunction and Infertility, Sexuality and Reproductive Issues, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: laboratory biomarker analysis, fertility assessment and management, management of therapy complications, ultrasound imaging; Other · Procedure
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 14 Years to 35 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions: Chemotherapy, multiple agents; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Polycystic Ovarian Syndrome
Interventions: Paleolithic diet, American Diabetes Association diet; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
Interventions: triapine, cisplatin, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions: Alemtuzumab; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Breast Cancer, Ovarian Cancer
Interventions: Culturally Tailored Genetic Counseling; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 85 Years · Female only
Enrollment: 204 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2012
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Ovarian Cancer
Interventions: Questionnaire, Interview; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2026
U.S. locations: 5
States / cities: West Hollywood, California • Iowa City, Iowa • New York, New York + 2 more

Conditions: Extragonadal Germ Cell Tumor, Ovarian Cancer, Testicular Germ Cell Tumor, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: carboplatin, cyclophosphamide, etoposide, autologous bone marrow transplantation; Drug · Procedure
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 120 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1993 – 2007
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Search by objective public record fields.

CT-2103 in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer

Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis

Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)

A Study to Evaluate the Effect of Elix Cycle Balance and Daily Harmony on Polycystic Ovary Syndrome

Myo-Inositol for Infertility in PCOS

Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer

Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer

Effect of Cinnamon Extract on Insulin Resistance in Polycystic Ovary Syndrome

Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC

Combination Therapy for Recurrent Ovarian Cancer

A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors

Young Women Diagnosed With Early Stage Ovarian Cancer: A Focus on Fertility Issues and Sexual Function

A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors

Radiolabeled Monoclonal Antibody in Treating Patients With Advanced Ovarian Epithelial Cancer

The Effect of Metformin Added to Clomiphene Citrate on Pregnancy Rates in Hyperandrogenic, Chronic Oligoovulatory or Anovulatory Women

Ovarian Damage in Young Premenopausal Women Undergoing Chemotherapy for Cancer

Phase II Study of Modified Triple Doublet Therapy in Women With Newly Diagnosed Mullerian Carcinoma

Paleo Versus Healthy ADA Diets for Treatment of Polycystic Ovarian Syndrome (PCOS)

3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer

A Phase I Study of Alemtuzumab in Patients With Relapsed Ovarian/Primary Peritoneal Cancer.

Genetic Counseling in African American Women

Biobehavioral and Sociodemographic Characteristics of Long Term Survivors of Ovarian Cancer

Carboplatin, Etoposide, Cyclophosphamide, and Autologous Bone Marrow Transplantation in Patients With Relapsed or Refractory Cancer